277 related articles for article (PubMed ID: 28985758)
1. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
[TBL] [Abstract][Full Text] [Related]
2. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
[TBL] [Abstract][Full Text] [Related]
3. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
[TBL] [Abstract][Full Text] [Related]
4. Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines
Colapietro A; Gravina GL; Petragnano F; Fasciani I; Scicchitano BM; Beirinckx F; Pujuguet P; Saniere L; Van der Aar E; Musio D; De Felice F; Mattei V; Martellucci S; Maggio R; Tombolini V; Festuccia C; Marampon F
J Oncol; 2020; 2020():9342732. PubMed ID: 32184826
[TBL] [Abstract][Full Text] [Related]
5. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
6. The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models.
Gravina GL; Mancini A; Colapietro A; Delle Monache S; Sferra R; Vitale F; Cristiano L; Martellucci S; Marampon F; Mattei V; Beirinckx F; Pujuguet P; Saniere L; Lorenzon G; van der Aar E; Festuccia C
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30871240
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
8. Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness.
Chiappalupi S; Riuzzi F; Fulle S; Donato R; Sorci G
Carcinogenesis; 2014 Oct; 35(10):2382-92. PubMed ID: 25123133
[TBL] [Abstract][Full Text] [Related]
9. Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.
Rossetti A; Petragnano F; Milazzo L; Vulcano F; Macioce G; Codenotti S; Cassandri M; Pomella S; Cicchetti F; Fasciani I; Antinozzi C; Di Luigi L; Festuccia C; De Felice F; Vergine M; Fanzani A; Rota R; Maggio R; Polimeni A; Tombolini V; Gravina GL; Marampon F
Int J Radiat Biol; 2021; 97(7):943-957. PubMed ID: 33979259
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
[TBL] [Abstract][Full Text] [Related]
11. c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines.
Gravina GL; Festuccia C; Popov VM; Di Rocco A; Colapietro A; Sanità P; Monache SD; Musio D; De Felice F; Di Cesare E; Tombolini V; Marampon F
Radiat Res; 2016 Apr; 185(4):411-22. PubMed ID: 27104757
[TBL] [Abstract][Full Text] [Related]
12. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
Marampon F; Bossi G; Ciccarelli C; Di Rocco A; Sacchi A; Pestell RG; Zani BM
Mol Cancer Ther; 2009 Mar; 8(3):543-51. PubMed ID: 19258428
[TBL] [Abstract][Full Text] [Related]
13. A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
Hüttner SS; Henze H; Elster D; Koch P; Anderer U; von Eyss B; von Maltzahn J
Mol Ther; 2023 Sep; 31(9):2612-2632. PubMed ID: 37452493
[TBL] [Abstract][Full Text] [Related]
14. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Belyea BC; Naini S; Bentley RC; Linardic CM
Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
[TBL] [Abstract][Full Text] [Related]
16. Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration.
Al-Ghabkari A; Qasrawi DO; Alshehri M; Narendran A
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1461-1469. PubMed ID: 31006845
[TBL] [Abstract][Full Text] [Related]
17. Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells.
Huot M; Caron M; Richer C; Djibo R; Najmanovich R; St-Onge P; Sinnett D; Raynal NJM
Cancer Chemother Pharmacol; 2021 Nov; 88(5):845-856. PubMed ID: 34331108
[TBL] [Abstract][Full Text] [Related]
18. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells.
Beccafico S; Morozzi G; Marchetti MC; Riccardi C; Sidoni A; Donato R; Sorci G
Carcinogenesis; 2015 Sep; 36(9):1071-83. PubMed ID: 26153023
[TBL] [Abstract][Full Text] [Related]
19. RAGE signaling deficiency in rhabdomyosarcoma cells causes upregulation of PAX7 and uncontrolled proliferation.
Riuzzi F; Sorci G; Sagheddu R; Sidoni A; Alaggio R; Ninfo V; Donato R
J Cell Sci; 2014 Apr; 127(Pt 8):1699-711. PubMed ID: 24554430
[TBL] [Abstract][Full Text] [Related]
20. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
